Abstract: The disclosure is directed to methods and compositions that include MNTF peptides and their analogs for cosmetic and dermatological purposes.
Abstract: A multi electrode and needle injection device for identifying and treating muscle pain using two simultaneous electrode EMG recordings to locate an active trigger point. The two electrodes are displaced so that one electrode detects EMG activity at the trigger point and the other detects EMG activity adjacent to the trigger point, within the same muscle. The combination of the electrodes with a drug delivery system allows the user to inject a medication locally at the trigger point to block the trigger point activity and reduce or eliminate muscle pain. The electrodes are on a hypodermic needle. The needle is used to both facilitate the location of the trigger points, and for treatment, by injecting a drug into the trigger points.
Abstract: The present invention relates to methods of treating an individual with diabetes mellitus by administering to said individual an effective amount of copper chelators, hydrazine compounds, and/or substrate analogues. The invention also relates to methods of treating an individual with diabetes mellitus by lessening fructosamine odixase activity in said individual. Provided within is disclosure pertaining to treatment, pharmaceutical compositions, dosage ranges, and uses of fructosamine oxidase enzyme inhibitors to lessen fructosamine oxidase activity.
Abstract: Dislcosed are methods and compositions for producing weight loss in a mammal by administration of a composition containing a weight loss effective amount of a noradrenaline stimulating compound such as ephedrine, mahuang (a plant source of ephedrine alkaloids), citrus aurantium (bitter orange), synephrine, norephedrine, psuedophedrine, a methylxanthine, such as caffeine or guarana, and a botanical COX inhibitor such as resveratrol polygonum cuspidatum, scutellaria baicalensis, turmeric, curcumin, rosmary, green tea, ocimum sanctum (holy basil), or ginger, instead of an NSAID such as aspirin, and optionally a free fatty acid reducing compound. The thermogenic formula is coupled with a growth hormone stimulating formulation containing L-arginine or L-omithine, L-lysine, and a free fatty acid reducing agent such as nicotinic acid. The thermogenic formula would preferably be administered in the daytime, and the growth hormone producing formula at nighttime.
Abstract: A method for selectively detecting the presence of C. parvum organisms in a sample. A method for selectively detecting the presence of C. parvum organisms and for detecting the presence of G. lamblia organisms, simultaneously, in a sample. A method for selectively detecting viable C. parvum organisms in a sample potentially containing viable C. parvum organisms. A method for selectively detecting viable C. parvum organisms and for detecting viable G. lamblia organisms, simultaneously. A method for selectively detecting infectious C. parvum organisms in a sample, and in another embodiment, additionally comprising detecting viable G. lamblia organisms in the sample, simultaneously. Kit for use in performing these methods.
Type:
Grant
Filed:
June 4, 1999
Date of Patent:
August 20, 2002
Assignee:
Metropolitan Water District of Southern California